📊 KALA Key Takeaways
Is KALA BIO, Inc. (KALA) a Good Investment?
KALA Bio exhibits critical operational and financial stress with zero revenue generation, indicating failed or stalled product commercialization despite being in the pharmaceutical sector. The company is burning $4.4M annually in free cash flow while carrying $26.9M in long-term debt against only $12.3M in total assets, creating severe solvency risk with negative interest coverage and minimal cash cushion of $1.8M.
KALA BIO is pre-revenue with substantial operating losses, negative equity, and sub-1.0 liquidity, signaling material financial stress. With deeply negative interest coverage and persistent cash burn, the business appears dependent on near-term external financing or a swift, uncertain shift to revenue.
Why Buy KALA BIO, Inc. Stock? KALA Key Strengths
- Strong short-term liquidity with 7.91x current ratio providing runway for near-term obligations
- Positive stockholders equity of $10.8M despite losses
- Recent financial data available (March 31, 2026) enables current assessment
- $21.1M cash provides short-term runway
- Asset-light profile with low capex ($1.46M)
- EPS loss improved YoY, suggesting some cost discipline
KALA Stock Risks: KALA BIO, Inc. Investment Risks
- Zero revenue suggests failed product commercialization or pre-commercial stage despite mature pharmaceutical company classification
- Debt-to-equity ratio of 2.50x with total debt exceeding total assets creates insolvency risk and refinancing pressure
- Negative operating and free cash flow of -$2.9M and -$4.4M respectively with no revenue growth path visible
- Negative interest coverage ratio of -1.2x indicates inability to service debt from operations
- Zero insider Form 4 filings in 90 days suggests lack of management confidence
- Liquidity shortfall: current ratio 0.75x and negative equity
- Sustained negative FCF (-$28.89M) with zero revenue
- High leverage and -19.9x interest coverage raise refinancing/dilution risk
Key Metrics to Watch
- Cash burn rate and runway to potential insolvency or financing event
- Revenue achievement from pipeline products or partnership announcements
- Debt restructuring, refinancing activity, or equity raise announcements
- Operating cash burn (OCF) and cash runway
- Debt service/interest coverage and upcoming maturities
KALA BIO, Inc. (KALA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.91x current ratio provides a solid financial cushion.
KALA Profit Margin, ROE & Profitability Analysis
KALA vs Healthcare Sector: How KALA BIO, Inc. Compares
How KALA BIO, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KALA BIO, Inc. Stock Overvalued? KALA Valuation Analysis 2026
Based on fundamental analysis, KALA BIO, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KALA BIO, Inc. Balance Sheet: KALA Debt, Cash & Liquidity
KALA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: KALA BIO, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-10.15 indicates the company is currently unprofitable.
KALA Revenue Growth, EPS Growth & YoY Performance
KALA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $420.0K | -$8.7M | $-3.41 |
| Q2 2023 | $2.1M | -$10.4M | $-4.36 |
| Q1 2023 | $1.4M | -$14.5M | $-6.99 |
| Q3 2022 | $420.0K | -$28.1M | $19.25 |
| Q2 2022 | $2.1M | -$28.1M | $-0.38 |
| Q1 2022 | $1.4M | -$30.4M | $-0.45 |
| Q3 2021 | $2.2M | -$27.9M | N/A |
| Q2 2021 | $833.0K | -$23.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KALA BIO, Inc. Dividends, Buybacks & Capital Allocation
KALA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for KALA BIO, Inc. (CIK: 0001479419)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KALA
What is the AI rating for KALA?
KALA BIO, Inc. (KALA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KALA's key strengths?
Claude: Strong short-term liquidity with 7.91x current ratio providing runway for near-term obligations. Positive stockholders equity of $10.8M despite losses. ChatGPT: $21.1M cash provides short-term runway. Asset-light profile with low capex ($1.46M).
What are the risks of investing in KALA?
Claude: Zero revenue suggests failed product commercialization or pre-commercial stage despite mature pharmaceutical company classification. Debt-to-equity ratio of 2.50x with total debt exceeding total assets creates insolvency risk and refinancing pressure. ChatGPT: Liquidity shortfall: current ratio 0.75x and negative equity. Sustained negative FCF (-$28.89M) with zero revenue.
What is KALA's revenue and growth?
KALA BIO, Inc. reported revenue of $0.0.
Does KALA pay dividends?
KALA BIO, Inc. does not currently pay dividends.
Where can I find KALA SEC filings?
Official SEC filings for KALA BIO, Inc. (CIK: 0001479419) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KALA's EPS?
KALA BIO, Inc. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KALA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, KALA BIO, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KALA stock overvalued or undervalued?
Valuation metrics for KALA: ROE of -15.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KALA stock in 2026?
Our dual AI analysis gives KALA BIO, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KALA's free cash flow?
KALA BIO, Inc.'s operating cash flow is $-2.9M, with capital expenditures of $1.5M.
How does KALA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -15.1% (avg: 15%), current ratio 7.91 (avg: 2).
Is KALA BIO, Inc. carrying too much debt?
KALA has a debt-to-equity ratio of 2.50x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 7.91 suggests adequate short-term liquidity.